Qinotto and Lilly Enter Research Collaboration and License Agreement

Core Insights - Qinotto, Inc. has entered a research collaboration and license agreement with Eli Lilly to develop next-generation antibody-based vehicles for brain transport [1][2] - The collaboration aims to optimize the delivery of large molecule therapeutics to the brain, leveraging Lilly's expertise and technological infrastructure [2] Company Overview - Qinotto is a biopharmaceutical company focused on the central nervous system (CNS) and is developing novel transport vehicles to deliver therapeutic products to the brain [3] - The company's proprietary blood-brain barrier (BBB) platform, QinoTrans, identifies novel targets on the BBB to facilitate the delivery of large molecules that typically cannot cross this barrier [3] - Qinotto aims to create first-in-class brain delivery vehicles that will serve as the foundation for a pipeline of advanced CNS products [3]